论文部分内容阅读
选取慢性病毒性乙型肝炎５０例及丙型肝炎２０例，应用胸腺肽α１和干扰素α１ｂ联合治疗６个月，治疗后其ＰＣＲＨＢＶＤＮＡ的阴转率为６８．０％，ＰＣＲＨＣＶＲＮＡ的阴转率为７０．０％，较对照组（干扰素α１ｂ）的ＰＣＲＨＢＶＤＮＡ阴转率４４．０％及ＰＣＲＨＣＶＲＮＡ的阴转率３０．０％为高（Ｐ＜０．０５）。通过治疗前、后检测Ｔ细胞亚群、ｓＩＬ２Ｒα及ＴＮＦα发现，治疗前ＣＤ＋８，ｓＩＬ２Ｒα和ＴＮＦα明显增高，经胸腺肽处理后，ＣＤ＋８，ｓＩＬ２Ｒα和ＴＮＦα均明显下降，相反ＣＤ＋４相应增高（Ｐ＜０．０１），说明胸腺肽是通过调整Ｔ细胞的活性，促进ＣＤ＋４的成熟来提高抗病毒的疗效。
Select 50 cases of chronic viral hepatitis B and 20 cases of hepatitis C, the application of thymosin α1 and interferon α1b combination therapy for 6 months after treatment of PCR-HBV DNA negative conversion rate was 68.0% PCR-HCV RNA negative conversion rate of 70.0%, compared with the control group (interferon α1b) PCR HBV DNA negative conversion rate of 44.0% and PCR HCV RNA RNA negative rate of 30.0% for the high (P <0.05). The levels of CD + 8, sIL2Rα and TNFα before and after treatment were significantly increased by detecting T cell subsets, sIL2Rα and TNFα before and after treatment. CD + 8, sIL2Rα and TNFα were significantly decreased after treatment with thymosin, but CD + 4 increased accordingly (P <0.01), indicating that thymosin can improve the anti-virus effect by regulating T cell activity and promoting the maturation of CD + 4.